On Friday, Cognition Therapeutics Inc (CGTX) stock saw a modest uptick, ending the day at $0.63 which represents no change from the prior close of of $0.63. The stock opened at $0.64 and touched a low ...

Fintel reports that on December 19, 2024, B. Riley Securities upgraded their outlook for Cognition Therapeutics ...

In this article, we’ll explore the recent developments behind this surge, delve into Cognition Therapeutics’ business, and offer a comparative analysis of the company’s year-to-date performance ...

Cognition Therapeutics (CGTX) announced topline results from the exploratory Phase 2 ‘SHIMMER’ study demonstrating CT1812 ...

H.C. Wainwright raised the firm’s price target on Cognition Therapeutics (CGTX) to $6 from $5 and keeps a Buy rating on the shares. The company ...

The price trend for Cognition Therapeutics, Inc. (CGTX) has been bearish lately and the stock has lost 9.6% over the past week. However, the formation of a hammer chart pattern in its last trading ...

Cognition Therapeutics' CT1812 improves dementia with Lewy bodies outcomes, reducing anxiety, hallucinations, and functional ...

B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up from $1. The ...

Fintel reports that on December 19, 2024, B. Riley Securities upgraded their outlook for Cognition Therapeutics (NasdaqGM:CGTX) from Neutral to Buy. As of December 3, 2024, the average one-year ...

Cognition Therapeutics (CGTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ...